An unexpected discovery in a herpes lab might bring relief to cancer patients
June 29, 2017
| By Sabin Russell / Fred Hutch News Service
Drs. Jia Zhu and Tao Peng made a unexpected discovery while searching for a treatment for herpes: The virus prompts skin cells to make a protein that keeps sensory nerves healthy, and might lead to a treatment for peripheral neuropathy, a side effect of chemotherapy.
Pritelivir reduces viral shedding and lesions better than valacyclovir, study shows
Dec. 20, 2016
| By Mary Engel / Fred Hutch News Service
The results of the phase 2, randomized, double-blind trial published today in JAMA showed that when people with genital herpes took a daily oral dose of pritelivir, they reduced their rate of viral shedding by half compared to when they took valacyclovir. They also had fewer genital sores and less pain.
New Hutch study predicts threshold of viral load for passing herpes from one person to another
March 25, 2014
| By Mary Engel
Fred Hutch researchers used mathematical models to predict viral loads below which transmission of the herpes virus is unlikely to occur. Preventing transmission is critical because there is no cure for herpes.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.